tiprankstipranks
Trending News
More News >
OptimizeRx Corporation (OPRX)
NASDAQ:OPRX
US Market
Advertisement

OptimizeRx (OPRX) Stock Statistics & Valuation Metrics

Compare
548 Followers

Total Valuation

OptimizeRx has a market cap or net worth of $267.31M. The enterprise value is $408.02M.
Market Cap$267.31M
Enterprise Value$408.02M

Share Statistics

OptimizeRx has 18,640,652 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,640,652
Owned by Insiders9.59%
Owned by Institutions34.18%

Financial Efficiency

OptimizeRx’s return on equity (ROE) is -0.17 and return on invested capital (ROIC) is -9.19%.
Return on Equity (ROE)-0.17
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-9.19%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee719.74K
Profits Per Employee-157.11K
Employee Count128
Asset Turnover0.54
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of OptimizeRx is ―. OptimizeRx’s PEG ratio is -0.65.
PE Ratio
PS Ratio0.97
PB Ratio0.76
Price to Fair Value0.76
Price to FCF18.61
Price to Operating Cash Flow23.16
PEG Ratio-0.65

Income Statement

In the last 12 months, OptimizeRx had revenue of 92.13M and earned -20.11M in profits. Earnings per share was -1.10.
Revenue92.13M
Gross Profit59.38M
Operating Income-13.71M
Pretax Income-19.39M
Net Income-20.11M
EBITDA-8.90M
Earnings Per Share (EPS)-1.10

Cash Flow

In the last 12 months, operating cash flow was 11.82M and capital expenditures -167.00K, giving a free cash flow of 11.66M billion.
Operating Cash Flow11.82M
Free Cash Flow11.66M
Free Cash Flow per Share0.63

Dividends & Yields

OptimizeRx pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.10
52-Week Price Change176.30%
50-Day Moving Average17.99
200-Day Moving Average13.34
Relative Strength Index (RSI)37.32
Average Volume (3m)283.40K

Important Dates

OptimizeRx upcoming earnings date is Feb 19, 2026, TBA (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateFeb 19, 2026
Ex-Dividend Date

Financial Position

OptimizeRx as a current ratio of 2.89, with Debt / Equity ratio of 3.11%
Current Ratio2.89
Quick Ratio2.89
Debt to Market Cap0.37
Net Debt to EBITDA-2.23
Interest Coverage Ratio-2.23

Taxes

In the past 12 months, OptimizeRx has paid 725.00K in taxes.
Income Tax725.00K
Effective Tax Rate-0.04

Enterprise Valuation

OptimizeRx EV to EBITDA ratio is -12.22, with an EV/FCF ratio of 22.76.
EV to Sales1.18
EV to EBITDA-12.22
EV to Free Cash Flow22.76
EV to Operating Cash Flow22.24

Balance Sheet

OptimizeRx has $19.52M in cash and marketable securities with $28.61M in debt, giving a net cash position of -$9.09M billion.
Cash & Marketable Securities$19.52M
Total Debt$28.61M
Net Cash-$9.09M
Net Cash Per Share-$0.49
Tangible Book Value Per Share$0.03

Margins

Gross margin is 65.31%, with operating margin of -14.88%, and net profit margin of -21.83%.
Gross Margin65.31%
Operating Margin-14.88%
Pretax Margin-21.04%
Net Profit Margin-21.83%
EBITDA Margin-9.66%
EBIT Margin-14.36%

Analyst Forecast

The average price target for OptimizeRx is $24.97, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$24.97
Price Target Upside74.13% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast24.19%
EPS Growth Forecast

Scores

Smart Score7
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis